Q1 Earnings Forecast for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Quanterix in a research note issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.16) EPS.

Separately, TD Cowen raised their target price on shares of Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

Shares of QTRX opened at $11.73 on Wednesday. The firm has a market cap of $451.89 million, a P/E ratio of -11.17 and a beta of 1.33. Quanterix has a 1 year low of $9.87 and a 1 year high of $29.70. The company has a 50 day simple moving average of $12.02 and a two-hundred day simple moving average of $12.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new position in Quanterix during the third quarter valued at $60,000. Peapack Gladstone Financial Corp bought a new position in shares of Quanterix in the 3rd quarter valued at about $131,000. SG Americas Securities LLC bought a new position in shares of Quanterix in the 3rd quarter valued at about $139,000. Canada Pension Plan Investment Board purchased a new position in Quanterix in the second quarter worth about $140,000. Finally, Hsbc Holdings PLC increased its stake in Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after acquiring an additional 3,279 shares during the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.